StockNews.com assumed coverage on shares of Trinity Biotech (NASDAQ:TRIB – Get Free Report) in a research note issued to investors on Friday. The brokerage set a “hold” rating on the stock.
Trinity Biotech Stock Performance
NASDAQ:TRIB opened at $0.76 on Friday. The stock has a market cap of $13.72 million, a price-to-earnings ratio of -0.34 and a beta of 1.03. The business has a fifty day moving average of $0.87 and a 200-day moving average of $1.46. Trinity Biotech has a 1 year low of $0.74 and a 1 year high of $3.55.
Institutional Trading of Trinity Biotech
An institutional investor recently raised its position in Trinity Biotech stock. Hunter Associates Investment Management LLC grew its stake in shares of Trinity Biotech plc (NASDAQ:TRIB – Free Report) by 7.8% in the 3rd quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 359,810 shares of the company’s stock after purchasing an additional 26,100 shares during the period. Hunter Associates Investment Management LLC owned about 4.72% of Trinity Biotech worth $390,000 as of its most recent SEC filing. Institutional investors and hedge funds own 78.97% of the company’s stock.
Trinity Biotech Company Profile
Trinity Biotech plc acquires, together with its subsidiaries, develops, acquires, manufactures, and markets medical diagnostic products for the clinical laboratory and point-of-care (POC) segments of the diagnostic market in the Americas and Ireland. The company offers clinical laboratory products, including diagnostic tests and instrumentation, which detects infectious diseases; sexually transmitted diseases consisting of syphilis and herpes; SARS-CoV-2; and epstein barr, measles, mumps, toxoplasmosis, cytomegalovirus, rubella, varicella and other viral pathogens, as well as products for the in-vitro diagnostic testing for haemoglobin A1c used in the monitoring and diagnosis of diabetes, and identifying those who are at a risk of developing diabetes.
Recommended Stories
- Five stocks we like better than Trinity Biotech
- Stock Market Sectors: What Are They and How Many Are There?
- Upstart’s Uptrend Is Just Getting Started: Its Time to Load Up
- How Can Investors Benefit From After-Hours Trading
- Archer Aviation Lands BlackRock Investment—What’s Next for ACHR?
- How to Evaluate a Stock Before Buying
- Buffett Buys More Occidental Petroleum—Sticking to His Playbook
Receive News & Ratings for Trinity Biotech Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Trinity Biotech and related companies with MarketBeat.com's FREE daily email newsletter.
